Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors

<p>Abstract</p> <p>Background</p> <p>Epithelial ovarian cancer survivors (EOCSs) frequently report multiple complaints after their treatment. The objective was to study somatic and mental morbidity in EOCSs associated with their Self- Rated Health (SRH) assessed by a single item.</p> <p>Findings were compared to age-matched controls from the general population.</p> <p>Methods</p> <p>In a cross -sectional follow-up design 189/287 (66%) EOCSs treated at The Norwegian Radiumhospital 1979–2003 responded to a mailed questionnaire on demographic data, and somatic and mental morbidity. SRH last week was rated on item #29 of the European Organization and Treatment of Cancer Quality of Life Questionnaire in 84/189 (97%) of responding EOCSs. For comparisons "good" and "poor" SRH groups were defined by the median score on the SRH item.</p> <p>Results</p> <p>EOCSs with "poor SRH" had higher level of somatic symptoms, anxiety, depression and fatigue than those with "good SRH" (p < .001). In multivariate analyses somatic symptoms, age and fatigue, were significantly associated with the SRH score in EOCSs, but not the cancer-related variables (FIGO stage, recurrence in < 6 months or chemotherapy ever). The model explained 70% of the variance in SRH in linear and 77% in logistic regression analyses. The distribution of the SRH scores in EOCSs did not differ significantly from that of normative controls; however a higher proportion of controls recorded a high SRH score.</p> <p>Conclusion</p> <p>SRH is strongly related to common somatic complaints, impairment and fatigue but not to cancer-related variables. A single question concerning SRH last week might be a quick screening method for collecting important information on symptoms in EOCSs, in addition to cancer – related questions.</p

Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma

Since 1992 we have prospectively included all head and neck cancer patients in our health region in a departmental based register. Our hospital takes care of all head and neck cancer patients in our health region consisting of approximately 1 million people. In 1997, we evaluated the results of the treatment of oropharyngeal cancer in the 1992–1997 period. On the basis of this evaluation, we changed our treatment policy for tonsillar and base of tongue carcinoma. We first changed the treatment for the lesions with worst prognosis, i.e., those with T3–T4 carcinomas, from radiotherapy only, to radical surgery and postoperative radiotherapy. We have since that time increasingly also operated the smaller oropharyngeal carcinomas. The 2 years’ overall survival and disease-specific survival for all patients diagnosed in the 1992–1997 period was 56 and 63%, respectively. The results from a similar group of patients in the 6 years’ period from 2000 to 2005, after the change in treatment, have increased to 83 and 88%. When we looked at the subgroup of patients in the 2000–2005 period treated with surgery and postoperative radiotherapy, 45 out of 69 patients (65%) presenting with an oropharyngeal cancer were fit for operation. With radical surgery and postoperative radiation therapy, the 2 years overall survival is now 91%. The 2-year disease-specific survival is 96% and the locoregional control is 98%. This is a marked improvement as compared to radiotherapy alone and definitely competitive with modern radiochemotherapy

Maintained CD40 and loss of polarised CD40 ligand expression in oral squamous cell carcinoma

BACKGROUND: CD40 and its ligand (CD40L) are involved in immune response and inhibition or induction of apoptosis in different tissues. Little is known about CD40 and CD40L in oral squamous cell carcinomas (OSCC). MATERIALS AND METHODS: CD40 and CD40L were immunohistochemically evaluated in fresh-frozen samples of OSCC (n = 24) and normal oral epithelium (OE, n = 10). RESULTS: A high proportion of OE-cells expressed CD40 (> 80%) and CD40L (> 90%) in the basal compartment compared to less than 1% CD40-positive and 1% CD40L-positive cells in the suprabasal cell layer, reflecting a zonal distribution. In well-differentiated and moderately-differentiated OSCC, there was a less pronounced zonal distribution of CD40 and a marked loss of CD40L compared to OE (p < 0.05). Poorly-differentiated OSCC maintained CD40 and markedly lost CD40L compared to OE (p < 0.05). Double immunostaining for CD40L and laminin in OE showed a basement membrane associated localisation of CD40L. CONCLUSION: In OSCC, loss of polarised expression of CD40L and maintained expression of CD40 might be involved in tumourigenesis and immune evasionLoro LL, Ohlsson M, Vintermyr OK, Liavaag PG, Jonsson R, Johannessen A